Changing R&D models in research-based pharmaceutical companies

New drugs serving unmet medical needs are one of the key value drivers of research-based pharmaceutical companies. The efficiency of research and development (R&D), defined as the successful approval and launch of new medicines (output) in the rate of the monetary investments required for R&D (input), has declined since decades. We aimed to identify, analyze and describe the factors that impact the R&D efficiency. Based on publicly available information, we reviewed the R&D models of major research-based pharmaceutical companies and analyzed the key challenges and success factors of a sustainable R&D output. We calculated that the R&D efficiencies of major research-based pharmaceutical companies were in the range of USD 3.2–32.3 billion (2006–2014). As these numbers challenge the model of an innovation-driven pharmaceutical industry, we analyzed the concepts that companies are following to increase their R&D efficiencies: (A) Activities to reduce portfolio and project risk, (B) activities to reduce R&D costs, and (C) activities to increase the innovation potential. While category A comprises measures such as portfolio management and licensing, measures grouped in category B are outsourcing and risk-sharing in late-stage development. Companies made diverse steps to increase their innovation potential and open innovation, exemplified by open source, innovation centers, or crowdsourcing, plays a key role in doing so. In conclusion, research-based pharmaceutical companies need to be aware of the key factors, which impact the rate of innovation, R&D cost and probability of success. Depending on their company strategy and their R&D set-up they can opt for one of the following open innovators: knowledge creator, knowledge integrator or knowledge leverager.

[1]  Stephen Frye,et al.  US academic drug discovery , 2011, Nature Reviews Drug Discovery.

[2]  J. Arrowsmith,et al.  Trial Watch: Phase II and Phase III attrition rates 2011–2012 , 2013, Nature Reviews Drug Discovery.

[3]  Monika Lessl,et al.  Grants4Targets: an open innovation initiative to foster drug discovery collaborations , 2014, Nature Reviews Drug Discovery.

[4]  J. DiMasi,et al.  Risks in new drug development: Approval success rates for investigational drugs , 2001, Clinical pharmacology and therapeutics.

[5]  O. Gassmann,et al.  Value Creation in the Pharmaceutical Industry: The Critical Path to Innovation , 2016 .

[6]  F. Sams-Dodd.  Target-based drug discovery: is something wrong? , 2005, Drug discovery today.

[7]  Bethan Hughes,et al.  2008 FDA drug approvals , 2009, Nature Reviews Drug Discovery.

[8]  R. Litan,et al.  The case for entrepreneurship in R&D in the pharmaceutical industry , 2010, Nature Reviews Drug Discovery.

[9]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[10]  D. Mutter,et al.  Cell death after high-LET irradiation in orthotopic human hepatocellular carcinoma in vivo. , 2011, In vivo.

[11]  F. Scherer,et al.  Mergers and innovation in the pharmaceutical industry. , 2013, Journal of health economics.

[12]  M. Dickson,et al.  Key factors in the rising cost of new drug discovery and development , 2004, Nature Reviews Drug Discovery.

[13]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[14]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[15]  Hector Hernandez Guevara,et al.  The 2015 EU Industrial R&D Investment Scoreboard , 2015 .

[16]  Asher Mullard,et al.  2010 FDA drug approvals , 2011, Nature Reviews Drug Discovery.

[17]  J. Garnier,et al.  Rebuilding the R&D engine in big pharma. , 2008, Harvard business review.

[18]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[19]  P. Danzon,et al.  Mergers and Acquisitions in the Pharmaceutical and Biotech Industries , 2004 .

[20]  Oliver Gassmann,et al.  Models for open innovation in the pharmaceutical industry. , 2013, Drug discovery today.

[21]  Martin Schneider,et al.  Grants4Targets - an innovative approach to translate ideas from basic research into novel drugs. , 2011, Drug discovery today.

[22]  B. Munos.  Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.

[23]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[24]  J. DiMasi,et al.  Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs , 2010, Clinical pharmacology and therapeutics.

[25]  M. Pangalos,et al.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.

[26]  R. Hambleton,et al.  A decade of innovation , 2008 .

[27]  Carmine Ornaghi.  Mergers and innovation in big pharma , 2009 .

[28]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[29]  Shreefal S. Mehta,et al.  Outsourcing A Core Competency , 2007 .

[30]  Asher Mullard,et al.  2011 FDA drug approvals , 2012, Nature Reviews Drug Discovery.

[31]  Nadine Roijakkers,et al.  Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns, and networks , 2006 .

[32]  K. Śmietana,et al.  Outlook for the next 5 years in drug innovation , 2012, Nature Reviews Drug Discovery.

[33]  Asher Mullard,et al.  2013 FDA drug approvals , 2014, Nature Reviews Drug Discovery.

[34]  M. Ratner.  Pfizer reaches out to academia—again , 2011, Nature Biotechnology.

[35]  J. DiMasi,et al.  Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009 , 2011, Clinical pharmacology and therapeutics.

[36]  Sean Ekins,et al.  Four disruptive strategies for removing drug discovery bottlenecks. , 2013, Drug discovery today.

[37]  L Lasagna,et al.  Cost of innovation in the pharmaceutical industry. , 1991, Journal of health economics.

[38]  F. Prinz,et al.  Believe it or not: how much can we rely on published data on potential drug targets? , 2011, Nature Reviews Drug Discovery.

[39]  Mahmud Hassan,et al.  Pharmaceutical R&D Productivity: The Role of Alliance , 2014 .

[40]  Charlotte Harrison.  GlaxoSmithKline opens the door on clinical data sharing , 2012, Nature Reviews Drug Discovery.

[41]  Pharma embraces open source models , 2010, Nature Biotechnology.

[42]  Asher Mullard.  2014 FDA drug approvals , 2015, Nature Reviews Drug Discovery.

[43]  J. J. Jehring.  The productivity crisis , 1967 .

[44]  B. Munos,et al.  Can Open‐Source Drug R&D Repower Pharmaceutical Innovation? , 2010, Clinical pharmacology and therapeutics.

[45]  The Impact of Collaborative and Risk-Sharing Innovation Approaches on Clinical and Regulatory Cycle Times , 2014, Therapeutic innovation & regulatory science.

[46]  John L. LaMattina,et al.  The impact of mergers on pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[47]  Pankaj Agarwal,et al.  Novelty in the target landscape of the pharmaceutical industry , 2013, Nature Reviews Drug Discovery.

[48]  Rosa M. Abrantes-Metz,et al.  Pharmaceutical Development Phases: A Duration Analysis , 2004 .

[49]  P. K. Owens,et al.  A decade of innovation in pharmaceutical R&D: the Chorus model , 2014, Nature Reviews Drug Discovery.

[50]  C. Tralau-Stewart,et al.  Drug discovery: new models for industry-academic partnerships. , 2009, Drug discovery today.

[51]  D. E. Clark.  Outsourcing lead optimization: the eye of the storm. , 2011, Drug discovery today.